FDA Panel Recommends Loosening Regulations for Certain Peptides Amid Rising Interest
A Food and Drug Administration (FDA) advisory panel has voted to broaden access to at least four peptides, amid increasing interest in these unapproved therapies. The decision was made during a two-day meeting focused on whether compounding pharmacies should be allowed to fill prescriptions for certain unapproved peptides. Peptides, which are short strings of amino acids, are naturally produced by the human body and are used in various approved medications. However, there is a growing demand for unapproved peptides, often marketed online for their purported benefits such as slowing aging or increasing muscle growth. The panel reviewed four peptides, including BPC-157, and voted 8-6 to add them to a list of substances that can be safely produced by compounding pharmacies. This decision does not equate to FDA approval, but it allows for their prescription under specific medical conditions. The panel's decision has sparked discussions about the safety and efficacy of these peptides, as many lack substantial s... 
